The enzyme telomerase elongates chromosome termini in most species. In human tissues, telomerase activity can be highly regulated, both at the level of expression of subunits of the enzyme, as well as by regulatory factors. Even modest alterations in enzyme activity are associated with several human disease syndromes[@R1], highlighting the importance of understanding the mechanistic basis for how telomerase is regulated. In budding yeast, the telomerase enzyme is composed of three proteins, Est1, Est2 and Est3, in a complex with the 1.3 kb TLC1 RNA[@R2]--[@R4], which provides a flexible scaffold on which telomerase assembles[@R5]. Est2 and TLC1 comprise the catalytic core of the enzyme, while the Est1 and Est3 subunits are regulatory proteins, as evidenced by the dramatically differential effects on telomerase function displayed by *est1*-Δ and *est3*-Δ strains, as assessed by *in vivo* versus *in vitro* assays. For example, *est1*-Δ strains exhibit an *in vivo* telomere replication defect that is indistinguishable from that of strains defective for the catalytic core of the enzyme[@R6], even though the Est1 protein is dispensable for *in vitro* catalysis by telomerase from both *S. cerevisiae* and *S. pombe*[@R7]--[@R10]. The overall architecture of the telomerase RNP appears to be surprisingly well conserved between the evolutionarily distant budding and fission yeasts[@R10]--[@R13], despite the fact that individual subunits have evolved rapidly at the primary sequence level.

A number of studies have established that the primary regulatory role for the budding yeast Est1 protein is to recruit telomerase to its site of action, through an electrostatic interaction with the single-strand telomere DNA binding protein Cdc13. Elucidation of this recruitment activity has relied on analysis of strains bearing separation-of-function mutations in *CDC13* and *EST1* (*cdc13-2* and *est1-60*, respectively), which has established that telomere maintenance relies on a direct association between the telomere-bound Cdc13 protein and the telomerase regulatory subunit Est1[@R14],[@R15]. In fact, the catalytic Est2 subunit can be re-localized to non-telomeric locations in the genome, including a site that is not adjacent to a DNA terminus, through a process that is dependent on the Cdc13-Est1 interaction[@R16]. Furthermore, Est1 and Est2, but not Cdc13, exhibit preferential association with shorter telomeres[@R17], consistent with the demonstration that telomere elongation is preferentially targeted to the shortest telomeres in a population[@R18]. These studies have established that the function of the Est1 and Cdc13 proteins that is impaired by the *cdc13-2* and *est1-60* mutations is recruitment of the catalytic core of telomerase to short telomeres (rather than to activate the enzyme, as alternatively proposed[@R19]).

In contrast to Est1, the Est3 telomerase subunit has been much less well-studied. Like Est1, the Est3 protein also performs a regulatory role, as it is also crucial for telomere replication *in vivo* but not for catalysis *in vitro*[@R8]. However, the molecular mechanism(s) underlying the Est3-specific regulatory function has not yet been elucidated. Even how Est3 physically associates with the telomerase complex has not been established: conflicting reports have suggested that Est3 interacts with telomerase through an interaction with Est2[@R4],[@R20] (JSL and VL, unpublished observations) or Est1[@R21],[@R22].

Using a panel of structure prediction programs, we report here that the Est3 protein consists of an OB (oligo-saccharide/oligo-nucleotide binding)-fold, and we have used this structural prediction to construct a functional map of one surface of the Est3 protein. Unexpectedly, the predicted OB-fold of Est3 exhibits structural similarity to an OB-fold domain in the mammalian TPP1 protein, as well as weaker similarity to that of the *O. nova* TEBP β protein. These two proteins are subunits of a telomere end-binding complex, called POT1/TPP1 in most species and TEBP α-β in the ciliate *O. nova*[@R23]--[@R28]. Both genetic and biochemical data argue that the POT1/TPP1 complex functions in role(s) distinct from that of telomerase, by protecting chromosome ends from events that would otherwise be lethal for cells[@R25],[@R29]--[@R34]. The functional differences between Est3 and TPP1 raise intriguing questions about the potential relationship(s) between structurally similar OB-fold domains present in complexes that perform different tasks at chromosome termini.

RESULTS {#S1}
=======

The Est3 telomerase protein contains a predicted OB-fold domain {#S2}
---------------------------------------------------------------

As a first step towards identifying structural homologs of the Est3 protein, we constructed an alignment of 20 Est3 protein sequences, displayed in [Fig. 1a](#F1){ref-type="fig"}. This alignment revealed a very low degree of sequence conservation; for example, the experimentally verified Est3 proteins from *S. cerevisiae*[@R35] and *Candida albicans*[@R36] exhibited only 18% identity and 15% similarity. The rapid divergence at the primary sequence level presumably explains why detection of Est3 homologs from more distant species has not yet been successful.

This alignment was subsequently used in a search of hidden Markov model (HMM) profiles for potential structural homologs in the Protein Data Bank, using the HHpred structure-prediction server[@R37]. The top-ranked hit was the OB-fold domain of the human TPP1 protein[@R38], with an *E*-value of 0.054 (P-value of 3.3 × 10^−6^) and a probability score of 93.8. Subsequent submission of the *S. cerevisiae* Est3 sequence to the structure-prediction servers SAM-T06[@R39] and FUGUE[@R40] similarly identified TPP1 as the top-ranked hit, with an *E*-value of 1.2 × 10^−2^ and a confidence value above 95%, respectively; SAM-T06 also identified the OB-fold of the *O. nova* TEPB β protein[@R41], with a score of 8 × 10^−1^. The *S. cerevisiae* Est3 protein was also submitted to the I-TASSER server, the highest scoring server at the CASP7 structure prediction competition[@R42]. Unlike the above three structure prediction programs, I-TASSER does not rely on global profile-profile searches and instead combines a fragmented structure prediction algorithm with fragment reassembly and ab initio folding of non-aligned regions. The two models for Est3 with the best confidence scores from the I-TASSER submission could be structurally aligned with the OB-fold of TPP1 using DALILITE, with Z-scores of 14.6 and 8.6 respectively (for comparison, TPP1 aligns with the *O. nova* TEBP β protein with a Z-score of 10.0).

Collectively, the above observations argue that the Est3 subunit of telomerase contains an OB-fold that is structurally similar to that of TPP1. We therefore constructed a 3-dimensional structural model of the *S. cerevisiae* Est3 protein, based on the HHpred profile-profile comparison. [Fig. 1b](#F1){ref-type="fig"} shows a ribbon representation of the predicted structure of Est3, overlaid with the structure of the OB-fold domain of TPP1. [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} demonstrates the relative position of this domain in Est3 and TPP1: the small Est3 protein consists of just the OB-fold, whereas TPP1 is a larger multi-domain protein.

Based on this structural prediction, an alignment of 16 TPP1 protein sequences was also constructed ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). TPP1 is similarly very divergent at the primary sequence level, and like Est3, TPP1 cannot be detected in a wide range of eukaryotic species. Due to the limited degree of conservation between these two protein families, it was not possible to construct an alignment composed of both TPP1 and Est3 sequences with high statistical confidence. Consistent with this, a comparison of these two independently constructed alignments revealed a limited number of residues that were conserved across both protein families. Only 3 residues, which were invariant or close to invariant, were common to both alignments (Trp21/Trp98, Asp86/Asp148, and Leu155/Leu204, in Est3 versus TPP1, respectively). Structural alignment of TPP1 and the HHpred-derived model of Est3 demonstrated that these residues share a common structural space (data not shown). An additional 7 amino acid positions, which were primarily hydrophobic, also appeared to be structurally conserved between the two protein families. These 10 residues are indicated on the alignments in [Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.

Notably, the 10 amino acids that are in common between Est3 and TPP1 are clustered in the interior of the core of the OB-fold, in both Est3 ([Fig. 2a](#F2){ref-type="fig"}) and TPP1[@R38], as calculated by solvent accessibility (data not shown). The proposed internal position of these 10 residues in the Est3 protein suggest that they make critical contributions to protein folding, which predicts that mutations in these residues should destabilize the protein. In agreement with this prediction, mutations in 8 of these 10 internal amino acids to alanine had a dramatic effect on steady-state protein levels, as assessed by western analysis of wild type and mutant Est3-(FLAG)~3~ derivatives ([Fig. 2b](#F2){ref-type="fig"}), consistent with a disruption in protein folding. This analysis therefore suggests that the limited number of amino acids that are reasonably well conserved between Est3 and TPP1 are primarily involved in protein folding and/or stability of the OB-fold.

Mapping the surface of the Est3 protein by mutagenesis {#S3}
------------------------------------------------------

Since mutations in internal residues are not, in most cases, useful for determining specific function(s) of a protein, we directed our attention to those amino acids that were likely to be on the surface of the Est3 protein, in order to identify a set of missense mutations that impaired Est3 activity due to loss of one or more biochemical property(s) of Est3. Missense mutations were introduced into 29 amino acids that were likely to be on the surface; residues were mutated to alanine and in some cases, to polar and/or charged residues. From an initial *in vivo* analysis of the effects of this larger set of mutations (data not shown), mutations in 10 amino acids were selected for a more detailed characterization, in parallel with mutations in two highly conserved internal residues (Trp21 and Asp86, [Fig. 2](#F2){ref-type="fig"}).

We first examined the impact of these mutations on Est3 function *in vivo*, using a loss-of-function assay that assessed telomere length ([Fig. 3a](#F3){ref-type="fig"}) and growth phenotypes ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) at several time points during serial propagation of mutant strains. A subset of mutant alleles exhibited telomere replication defects comparable to that of the *est3*-Δ null strain: telomeres were extremely short and the strains eventually exhibited the senescence phenotype that is a hallmark of a strain bearing a null mutation in telomerase[@R6]. These severely defective alleles included mutations in one of the predicted internal alleles (Asp86) as well two highly conserved potential surface residues (Arg110 and Glu104). Strains expressing mutations in the remaining 8 residues displayed a telomere replication defect that was only slightly less pronounced, with telomere lengths that were 150 to 200 bp shorter (for a subset of the mutations in Trp21, Asn117, Asp166 and Val168) or 100 to 150 bp shorter (for mutations in Lys68, Lys71, Glu114, Thr115 and Asp164) than that of the wild type *EST3* strain.

Consistent with the predicted location of these residues on the surface of the Est3 protein, mutations in these 10 residues had little or no effect on protein stability, as monitored by western analysis ([Fig. 3b](#F3){ref-type="fig"}). However, this relatively crude assessment of protein stability cannot rule out more subtle defects in protein folding. We therefore subjected these mutations to an alternative test of protein stability, by examining whether each of these mutant Est3 proteins, when expressed at high levels in an *EST3* strain, would be capable of disrupting telomere replication. Such dominant negative phenotypes are often used to infer that the mutant protein in question is functional enough (i.e. properly folded) to perform a subset of the activities of the wild type protein, and hence interfere with the function of the wild type protein. Two assays were used to assess potential dominant negative phenotypes: synthetic lethality in a *EST3 yku80*-Δ strain ([Fig. 3c](#F3){ref-type="fig"}) and telomere length in an *EST3 YKU80* strain ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). The synthetic lethality assay is based on prior observations demonstrating that a *yku80*-Δ strain is highly sensitized to defects in telomerase, resulting in severe growth defects or even lethality ([@R43] and data not shown). To assess the validity of this assay, we examined mutations in two internal residues: over-expression of the Est3-W21A and Est3-D86A proteins failed to confer a synthetic lethal phenotype in the *EST3 yku80*-Δ strain ([Fig. 3c](#F3){ref-type="fig"}), consistent with the fact that both of these mutations reduced protein stability ([Fig. 3b](#F3){ref-type="fig"}). In contrast, most of the mutations in the 10 proposed surface residues conferred some degree of synthetic lethality in the *yku80*-Δ strain, ranging from very severe to more modest effects on growth ([Fig. 3c](#F3){ref-type="fig"}).

The results from this assay also were supported by a more direct examination of telomere length in an *EST3 YKU80* strain, when either wild type or mutant Est3 proteins were over-expressed. Increased expression of the wild type Est3 protein had a very modest effect on telomere length, with a telomere length decline of ≤ 50 bp; in contrast, over-expression of the Est3-W21A mutant protein had no effect on telomere length, further confirming that the W21A mutation creates an unfolded protein ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). The effects on telomere length in the *EST3 YKU80* strain correlated extremely well with the synthetic lethal assay in the *EST3 yku80*-Δ strain. For example, over-expression of the Est3-D164A mutant protein resulted in both substantial telomere shortening and a severe synthetic growth defect, whereas over-expression of the Est3-D164R protein displayed virtually no dominant negative effects in either assay ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). A stringent interpretation of these results is that the D164A mutation impairs a specific function of Est3, whereas the D164R mutation creates a mutant protein that is at least partially unfolded and thus unable to confer a dominant negative phenotype when over-expressed.

The data in [Fig. 3a and Fig. 3c](#F3){ref-type="fig"} indicated that this panel of *est3*^−^ mutations could be classified on the basis of their relative behavior in the loss-of-function and dominant negative assays. Mutations in internal residues, such as *est3-W21A* and *est3-D86A*, were at one extreme end of the spectrum, with no dominant negative phenotype despite a severe loss-of-function defect, whereas mutations such as *est3-R110A* and *est3-R110E* were at the opposite end, with a strong defect in both assays. A graphical representation of the relative effect of these mutations in these two assays ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}) demonstrates that for most mutations, there is an excellent correlation between the severity of the defects in the loss-of-function and dominant negative assays. This is consistent with the premise that these mutations perturb the surface of the protein, which suggests that at least a subset of these may be "separation-of-function" alleles that have specifically lost a single biochemical activity associated with the Est3 telomerase subunit. For a small subset of mutations, however, there is a roughly inverse correlation, suggesting that loss of function in these mutant proteins is potentially due to protein destabilization. For example, the *est3-K68E* mutation has a loss-of-function defect roughly comparable to that of *est3-K68Y* but a greatly reduced effect in the dominant negative assay; the Est3-K68E mutant protein also exhibits a modest reduction in protein levels ([Fig. 3b](#F3){ref-type="fig"}). Mutations with little or no dominant negative phenotype (in particular, K68E and D164R) therefore were not included in the analysis described in the subsequent section.

A binding site for telomerase maps to one surface of the OB-fold {#S4}
----------------------------------------------------------------

To determine whether this collection of mutations included separation-of-function alleles, the association of each mutant Est3 protein with the telomerase holoenzyme was examined using co-immunoprecipitation of Est3-(FLAG)~3~ with TLC1. Each mutation was introduced into the Est3-(FLAG)~3~ construct, and Northern analysis of anti-FLAG immunoprecipitates were analyzed with probes to detect the telomerase TLC1 RNA, as well as the unrelated U1 RNA.

Strikingly, several of the most defective alleles, based on the *in vivo* analysis shown in [Fig. 3](#F3){ref-type="fig"}, still retained association with telomerase. Mutations in residues Lys71, Arg110 and Asp164 all exhibited wild type levels of co-immunoprecipitation with TLC1 ([Fig. 4a](#F4){ref-type="fig"}), arguing that a property other than interaction with the telomerase RNP is affected. In contrast, mutations in a second set of residues (Glu114, Thr115, Asn117 and Glu104) clearly impaired the ability of the Est3 protein to bind telomerase, with a reduction of 10-fold or more in co-immunoprecipitation with TLC1 ([Fig. 4b](#F4){ref-type="fig"}). It is worth re-emphasizing that mutations in both groups of residues exhibited strong dominant negative phenotypes when over-expressed, indicating that the absence of a dominant negative phenotype was not simply due to a difference in whether the Est3 protein associated with telomerase or not.

Three residues (Val168, Lys68 and Asp166) exhibited variable effects in the TLC1 co-immunoprecipitation assay, depending on the mutation ([Fig. 4c](#F4){ref-type="fig"}). For two of these residues (Val168 and Lys68), we propose that their primary role is a function other than mediating binding of the Est3 protein to telomerase, for the following rationale. The *est3-V168Y* mutation had a reasonably strong *in vivo* telomere replication defect but the mutant protein nevertheless retained wild type levels of association with telomerase; furthermore, the very modest decrease in telomerase association displayed by the Est3-V168D mutant protein could not account for the severity of the *in vivo est3-V168D* defect. In a similar manner, the mutant Est3-K68S protein bound telomerase at wild type levels, even though the *est3-K68S* strain exhibited a more severe in vivo defect than the *est3-K68Y* strain. In contrast, the *est3-D166R* strain displayed a far more severe *in vivo* defect (in both the loss-of-function and dominant negative assays) than the *est3-D166A* strain, arguing that a primary function of Asp166 is to contribute to the telomerase binding site of Est3.

[Fig. 4d](#F4){ref-type="fig"} maps these two groups of amino acids -- those that mediate association of Est3 with telomerase (indicated in red) and those that have a separate distinct function (indicated in yellow) -- on the proposed structure of Est3. Notably, four of the residues that are required for binding of Est3 to telomerase (Glu114, Thr115, Asn117, and Asp166) all cluster on one face of the OB-fold, with a fifth residues (E104) immediately adjacent. Thus, this analysis has identified a binding site for telomerase on the proposed surface of Est3 (note, however, that since this is a predicted structure, the specific orientation of these five residues relative to each other cannot be precisely determined). The remaining residues perform an additional function by Est3, as yet to be determined; notably, several of these residues (Arg110, Asp164 and Val168) immediately bracket the telomerase binding site on Est3, suggesting that this interaction face is not solely functioning to bring Est3 to the complex but it is also a site of an additional critical activity mediated by Est3.

DISCUSSION {#S5}
==========

The predicted 3-dimensional conformation of the Est3 telomerase protein provides a basis for generating separation-of-function mutations in residues that are likely to be on the protein surface. The identification of analogous separation-of-function mutations in *CDC13*[@R14], and subsequently in *EST1*[@R15] was instrumental in elucidating the regulatory role of the Est1 telomerase subunit. However, the initial mutation (*cdc13-2*) was a fortuitous discovery, resulting from an extremely labor-intensive mutagenesis screen[@R6]. In contrast, using structural predictions to restrict mutagenesis to proposed surface residues offers an alternative, and much more rapid, means of generating this particular class of alleles.

The directed mutagenesis approach has its limitations, however. In particular, our data illustrate the importance of analyzing missense mutations other than just alanine, often the default amino acid for site-directed mutagenesis, due its small size and amphipathic characteristics. For example, changing Val168 or Asn117 to alanine had no phenotypic consequences ([Fig. 3](#F3){ref-type="fig"}); the role of each of these two amino acids in Est3 function was only uncovered with additional mutagenesis. In addition, while the effects of mutations in the 10 predicted surface residues is consistent with the proposed Est3 structure that in [Fig. 4c](#F4){ref-type="fig"}, it is important to emphasize that this is only a model. In particular, the conformation of the extended β1 -- β2 and β4 -- β5 loops is an open question, as evidenced by the fact the different structure prediction servers handled these two regions differently (data not shown). However, the results from the protein stability and over-expression dominant negative assays increase the likelihood that we have identified functionally important surface residues. Furthermore, the availability of separation-of-function *est3*^−^ mutations should allow a genetic test of the proposed telomerase interaction surface depicted in [Fig. 4c](#F4){ref-type="fig"}, through the identification of reciprocal mutations in either *EST1* or *EST2* that suppress this particular class of *est3*^−^ defects.

The unexpected discovery of a structural relationship between a domain shared by Est3 and TPP1 might suggest that these two proteins are orthologs, i.e. two proteins with common ancestry that are structurally, and presumably functionally, related but separated by speciation. Although this is an intriguing speculation, we would argue against this idea based on what is currently known about these two proteins. Est3, as a 20 kDa subunit of telomerase, and TPP1, as a 58 kDa subunit of an end-binding complex, perform functionally distinct tasks at chromosome ends. The Est3-containing telomerase complex is responsible for enzymatically elongating the G-rich strand of the telomere, whereas the TPP1-POT1 heterodimer is crucial for protecting this telomeric G-rich overhang, once synthesized. Resolving the question of whether these two proteins are orthologs may rely on identification of additional TPP1 and Est3 protein sequences. In particular, identification of TPP1 and Est3 in the same species would definitively argue against the orthology model.

Nevertheless, the identification of structurally similar domains in Est3 and TPP1 may point to one or more biochemical properties shared by these two proteins. A recent study has shown that TPP1 can be co-immunoprecipitated with a TERT-containing complex[@R44], which suggests that the telomerase interaction site on Est3 may correspond to a similar site on TPP1. In fact, although Est3 and TPP1 share extremely limited primary sequence identity overall, three amino acids that are part of the telomere interaction site in Est3 have conserved structural counterparts in TPP1. We are currently testing whether over-expression of TPP1, bearing mutations in these three residues, will have a dominant negative effect on telomere length in human cells, analogous to the effects that we have observed with Est3.

The POT1/TPP1 complex has also been shown to act as a processivity factor for human telomerase *in vitro*[@R38]. Whether Est3, either alone or in combination with other proteins (such as Est1), functions in an analogous manner, is unclear. In *C. albicans*, null mutations in *EST1* or *EST3* result in primer-specific defects, as telomerase lacking either of these two subunits is unable to elongate a subset of telomeric primers[@R21],[@R45]. We have observed even more severe consequences on telomerase activity in extracts prepared from *est1*-Δ or *est3*-Δ strains of a related yeast, *S. castellii*: loss of either Est1 or Est3 results in an almost completely inactive enzyme, with all primers tested (JSL and VL, unpublished data). This is in sharp contrast to the situation in both *S. cerevisiae* and the more evolutionarily distant *S. pombe*, where loss of *EST1* function has no apparent effect on telomerase activity[@R7],[@R8],[@R10]. These species-specific variations may be due to differences in how the telomerase enzyme is assembled in different yeast species. Lue and colleagues have recently reported that Est1 and Est3 mutually depend on each other for association with the telomerase RNP in *C. albicans*[@R21], in contrast to what has been observed in *S. cerevisiae*[@R4]. Alternatively, it is possible that complete loss of a regulatory subunit, as the result of a deletion mutation, may destabilize the catalytic core of telomerase more substantially in some species than in others. Thus, whether the effects observed with the *S. castellii* and *C. albicans* enzymes will be representative of an evolutionarily conserved role for Est1 or Est3 in enzyme activity will require further study; the separation-of-function mutations described here may be useful in this regard.

Finally, we point out that the 10 residues presented in this study were chosen from a panel of missense mutations introduced into 29 residues, which represents \~50% of the amino acids predicted to reside on the surface of the Est3 protein. However, since this larger set consisted primarily of alanine mutations, it is likely that far less than 50% of the functional surface of Est3 has been probed, as discussed above. Successful construction of a comprehensive map of the functional surface of a protein therefore cannot rely solely on directed mutagenesis. Our study provides one such alternative, by using forward, rather than directed, mutagenesis, and screening for dominant negative phenotypes. Furthermore, it is worth noting that such a strategy, even in the absence of a predicted structure, is likely to target surface residues.

METHODS {#S6}
=======

Strains and plasmids {#S7}
--------------------

The strains used for the loss-of-function and dominant negative assays shown in [Fig. 3](#F3){ref-type="fig"} were YVL3057 (*MAT***a** *est3-Δ::LYS2 ura3-52 lys2*-801 *trp1*-Δ1 *his3*-Δ200 *leu2*-Δ1/p *CEN URA EST3*) and YVL3142 (*MAT***a** *yku80-Δ::KAN ura3-52 lys2*-801 *trp1*-Δ1 *his3*-Δ200 *leu2*-Δ1/p *CEN URA YKU80*), respectively. [Supplementary Table 1](#SD2){ref-type="supplementary-material"} lists the plasmids used in this study; the frameshift that is present in the genomic *EST3* gene[@R35] has been corrected in these constructs. Following the introduction of missense mutations by site-directed mutagenesis, we sequenced the entire *EST3* gene and/or sub-cloned the relevant portion of the mutant *est3*^−^ allele into an unmutagenized backbone, to eliminate unlinked mutations. The biochemical experiments shown in [Fig. 3b](#F3){ref-type="fig"} and [Fig. 4](#F4){ref-type="fig"} were performed in the protease-deficient strain JB811 (*MAT***a** *leu2 trp1 ura3-52 prb^−^ prc^−^ pep4-3*).

Sequence alignments {#S8}
-------------------

The Est3 sequences shown in the alignment in [Fig. 1a](#F1){ref-type="fig"} were identified by successive BLAST searches, starting with iterative PSI-BLAST searches of the non redundant (NR) database using the *S. cerevisiae* and *C. albicans* Est3 protein sequences as seeds. Homologs recovered from these two initial searches with a score of at least 1 × 10^−10^ were subsequently used to search available fungal genomes from the FGI, JGI and Sanger center, using BLASTP and TBLASTN. TPP1 homologs were identified through BLASTP searches of the NCBI NR database and ENSEMBL genome database. Predicted homologs were considered legitimate if the original and reciprocal BLASTP *E*-value with experimentally characterized homologs was at least 1 × 10^−5^. TPP1 sequences were aligned with the EXPRESSO alignment program[@R46]. Est3 sequences were aligned using the COMBINE feature of the TCOFFEE server to combine alignments generated by PROMALS and MCOFFEE[@R47],[@R48].

Structure predictions {#S9}
---------------------

A full-length alignment of all identified Est3 homologs was used as a seed for structural prediction with the online server HHpred, allowing for more homologous sequences to be used in calculation of the profile than are available in the NR database. Multi-template modeling (HHpred2 method) was used for super-HMM generation, and the 3D model based on the resulting HMM was generated with the program MODELLER[@R49]. Predictions from the online servers SAM-T06, FUGUE and I-TASSER were performed using default settings with a single protein sequence submission. The resulting models from prediction servers were subsequently compared with each other, and with TPP1, using the server DALILITE, to insure a similar global topology[@R50]. The structural alignments from these comparisons were visualized with PyMol to insure the calculated similarity resided within the core of the predicted OB fold.

Genetic and biochemical analysis of mutant proteins {#S10}
---------------------------------------------------

To monitor loss-of-function phenotypes, plasmids expressing mutant alleles of *EST3* (introduced into pVL2537, expressing an untagged version of the Est3 protein under the control of the native *EST3* promoter and present on a single copy CEN plasmid) were transformed into freshly derived *est3*-Δ derivatives of YVL3057, following loss of the *EST3 URA3* plasmid present in the strain; telomere length and senescence were assayed as described previously[@R6]. Dominant negative phenotypes were determined following transformation of *est3*^−^ mutations (introduced into pVL1024, a 2 µ plasmid expressing the Est3 protein under the control of the *ADH* promoter) into YVL3142, and potential synthetic lethal effects were assessed as described previously[@R43]. Est3-(FLAG)~3~ protein levels were determined from whole cell extracts of the JB811 strain transformed with pVL2076, or mutant derivatives of pVL2076, examined on 15% SDS-PAGE gels, which were subsequently probed simultaneously with anti-FLAG (Sigma; 1:5000) and anti-PGK (Invitrogen; 1:5000) antibodies. Co-immunoprecipitation of Est3 with TLC1 was examined in the protease-deficient strain JB811, transformed with plasmids expressing wild type or mutant alleles of Est3-(FLAG)~3~. The efficiency of co-immunoprecipitation of the wild type Est3-(FLAG)~3~ protein with TLC1 was \~ 20 to 40%, even in the presence of the genomic wild type *EST3* gene, and was not appreciably enhanced in an *est3*-Δ derivative of JB811 (data not shown); the efficiency of co-immunoprecipitation of the unrelated U1 RNA was \~0.1 to 0.5%. Extract preparation, immunoprecipitation protocols and northern analysis were performed as described previously[@R43]; anti-FLAG M2 agarose beads and HRP-conjugated anti-FLAG M2 antibody (Sigma) were used for immunoprecipitation and western analysis, respectively. Northerns were simultaneously probed with a 1.3 kb TLC1 restriction fragment, prepared by random-primed labeling, and a 23-mer oligomer that recognizes the U1 snRNA, prepared by end-labeling.
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![Est3 is an OB-fold-containing protein with structural similarity to the OB-fold of TPP1. (**a**) Alignment of the proposed OB-fold domain of the Est3 protein; aa 16 to 173 of the 181 amino acid *S. cerevisiae* protein is shown. Black arrowheads indicate 3 invariant, or nearly invariant, residues that are common to the Est3 and TPP1 protein families, and white arrowheads indicate an additional 7 amino acids that appear to be conserved between the two proteins (see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} for an alignment of TPP1). The position of TPP1 secondary structure assignments[@R38] are indicated (α helices and β strands, as cylinders and arrows, respectively), based on the structural comparison between Est3 and TPP1 shown in [Fig. 1b](#F1){ref-type="fig"}; the C-terminal α helix (αC) present in TPP1 could not be detected in Est3. (**b**) A ribbon representation of the predicted structure of Est3 (aa 16 to 173, indicated in blue), overlaid with the structure of the OB-fold domain of TPP1 (aa 93 to 222, indicated in red).](nihms84734f1){#F1}

![Residues that are conserved between Est3 and TPP1 are located in the core of the OB-fold. (**a**) Residues common to Est3 and TPP1 (indicated by arrowheads in the alignments shown in [Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) are depicted in cyan on a wire mesh diagram representing the surface area of the model for Est3, overlaid on a ribbon representation of the OB-fold. (**b**) Steady-state protein levels of wild type and mutant Est3-(FLAG)~3~ proteins were assessed by western analysis, by simultaneously probing with anti-FLAG and anti-PGK antibodies. For each mutant construct, the Est3-(FLAG)~3~ protein signal was quantitated, relative to that of the PGK signal, and normalized relative to wild type Est3-(FLAG)~3~ protein. The average of two samples prepared in parallel is shown.](nihms84734f2){#F2}

![Detailed phenotypic analysis of mutations in predicted surface residues of Est3. (**a**) Telomere length analysis: an *est3*-Δ strain was transformed with single-copy plasmids expressing either a mutant allele or the wild type *EST3* gene and propagated for \~80 cell divisions and examined for telomere length, as described previously. The senescence phenotype displayed by a subset of these mutant strains is shown in [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}. (**b**) Steady state levels of wild type and mutant derivatives of Est3-(FLAG)~3~ proteins were determined as described in [Fig. 2c](#F2){ref-type="fig"}. (**c**) Dominant negative phenotypes of *est3*^−^ mutant alleles: high copy (2 µ) plasmids expressing wild type and mutant alleles of *EST3*, under control of the ADH promoter, were transformed into *a yku80*-Δ/p *YKU80 URA3* strain and subsequently examined for growth by plating 5-fold serial dilutions of equivalent numbers of cells on media that that selects for loss of the *YKU80* plasmid. Growth of the *yku80*-Δ/pADH-*est3*^−^ strains was examined at both 30° and 32° C, based on our prior observations showing that synthetic growth defects displayed by *yku80*-Δ strains are enhanced by even a modest increase in temperature (data not shown).](nihms84734f3){#F3}

###### 

An interaction surface on one face of the OB-fold mediates association of Est3 with the telomerase enzyme. **(a) -- (c)** Association of mutant Est3 proteins with telomerase. Extracts from asynchronous log-phase cultures, expressing mutant or wild type Est3-(FLAG)~3~ proteins, were immunoprecipitated with anti-FLAG antibody, and immunoprecipitates were analyzed by Northern blotting to detect the TLC1 telomerase RNA or an unrelated (U1) RNA, and by western blotting to detect Est3-(FLAG)~3~; input samples for the Northern and western analysis are 2% and 10%, respectively. The efficiency of TLC1 co-immunoprecipitation was normalized to Est3-(FLAG)~3~ protein levels in the immunoprecipitates, and the first wild type sample arbitrarily set to 1.0; absolute efficiency was between 20 and 40%. Representative samples are shown for each set of mutants. **(d)** Residues that mediate binding of Est3 to telomerase (Glu104, Glu114, Thr115, Asn117, and Asp166) are depicted in red, and residues that perform a separate function (Lys68, Lys71, Arg110, Asp164 and Val168) are depicted in yellow, on a wire mesh model of Est3, overlaid on a ribbon representation of the OB-fold. Note that because this is a predicted structure, the exact relative position of these 10 residues, relative to each other, is not precisely determined.
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